Loading
CATB-101 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
CatenaBio describes CATB-101 in AACR 2026 abstract 6928. The two payloads inhibit topoisomerase I and tubulin. Cell-derived and patient-derived xenografts and non-GLP monkey studies are preclinical evidence; they do not demonstrate efficacy or a safer therapeutic window in patients. The abstract supports development, without a human response or survival readout.
Dual-payload anti-TROP2 antibody-drug conjugate delivering inhibitors of DNA processing and microtubule function. Connects to TROP2.
1.CATB-101's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CATB-101" OR ABSTRACT:"CATB-101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CATB-101, not a curated reading list.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/